S100A8 and acute myeloid leukemia: Interestingly, elevated S100A8/A9 levels predict Venetoclax resistance in acute myeloid leukemia [49], suggesting that modulation of calcium-binding proteins could influence both efficacy and toxicity profiles of BCL2 inhibitors.